MX2021007438A - Vectores de orthopoxvirus modificados. - Google Patents
Vectores de orthopoxvirus modificados.Info
- Publication number
- MX2021007438A MX2021007438A MX2021007438A MX2021007438A MX2021007438A MX 2021007438 A MX2021007438 A MX 2021007438A MX 2021007438 A MX2021007438 A MX 2021007438A MX 2021007438 A MX2021007438 A MX 2021007438A MX 2021007438 A MX2021007438 A MX 2021007438A
- Authority
- MX
- Mexico
- Prior art keywords
- modified orthopoxvirus
- vectors
- orthopoxvirus vectors
- modified
- amenability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784372P | 2018-12-21 | 2018-12-21 | |
| US201962872699P | 2019-07-10 | 2019-07-10 | |
| US201962930524P | 2019-11-04 | 2019-11-04 | |
| PCT/CA2019/051899 WO2020124274A1 (en) | 2018-12-21 | 2019-12-20 | Modified orthopoxvirus vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007438A true MX2021007438A (es) | 2021-09-21 |
Family
ID=71100021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007438A MX2021007438A (es) | 2018-12-21 | 2019-12-20 | Vectores de orthopoxvirus modificados. |
| MX2021007439A MX2021007439A (es) | 2018-12-21 | 2019-12-20 | Vectores de orthopoxvirus modificados. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007439A MX2021007439A (es) | 2018-12-21 | 2019-12-20 | Vectores de orthopoxvirus modificados. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220056480A1 (enExample) |
| EP (2) | EP3898997A4 (enExample) |
| JP (2) | JP2022514420A (enExample) |
| KR (2) | KR20210132003A (enExample) |
| CN (2) | CN113661246A (enExample) |
| AU (2) | AU2019404639A1 (enExample) |
| BR (2) | BR112021012078A2 (enExample) |
| CA (2) | CA3124301A1 (enExample) |
| CL (1) | CL2021001646A1 (enExample) |
| CO (1) | CO2021009354A2 (enExample) |
| EC (1) | ECSP21053474A (enExample) |
| IL (2) | IL284180A (enExample) |
| MX (2) | MX2021007438A (enExample) |
| PE (1) | PE20212307A1 (enExample) |
| PH (1) | PH12021551436A1 (enExample) |
| SG (1) | SG11202106460XA (enExample) |
| TW (1) | TW202039851A (enExample) |
| WO (2) | WO2020124273A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10612005B2 (en) | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| JP6915792B1 (ja) * | 2020-10-01 | 2021-08-04 | 国立大学法人鳥取大学 | 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| JP2025503721A (ja) * | 2022-01-17 | 2025-02-04 | ノイスコム アーゲー | がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター |
| CN119677861A (zh) * | 2022-06-10 | 2025-03-21 | 特兰斯吉恩股份有限公司 | 表达白介素-12的重组病毒 |
| IL318055A (en) * | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
| CN119923267A (zh) * | 2022-07-27 | 2025-05-02 | 阿斯利康(瑞典)有限公司 | 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合 |
| CN115947797B (zh) * | 2022-08-02 | 2024-07-05 | 青岛硕景生物科技有限公司 | 猴痘病毒重组抗原及其应用 |
| WO2024130212A1 (en) | 2022-12-16 | 2024-06-20 | Turnstone Biologics Corp. | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors |
| CN116200349A (zh) * | 2023-01-18 | 2023-06-02 | 中国医学科学院病原生物学研究所 | 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN118240879A (zh) * | 2023-11-01 | 2024-06-25 | 上海市重大传染病和生物安全研究院 | 骨架质粒、重组质粒以及猴痘病毒颗粒和应用 |
| WO2026047314A1 (en) * | 2024-08-28 | 2026-03-05 | University Of Surrey | Recombinant vector |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2150495T5 (es) * | 1993-05-19 | 2007-02-16 | Schering Corporation | Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos. |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| AU2003290528A1 (en) * | 2002-10-15 | 2004-05-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
| RU2503717C2 (ru) * | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| RS65104B1 (sr) * | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CN106520778A (zh) * | 2015-09-09 | 2017-03-22 | 北京锤特生物科技有限公司 | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 |
| WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| SG11202006457YA (en) * | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
-
2019
- 2019-12-20 EP EP19898487.4A patent/EP3898997A4/en not_active Withdrawn
- 2019-12-20 TW TW108147116A patent/TW202039851A/zh unknown
- 2019-12-20 AU AU2019404639A patent/AU2019404639A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022872A patent/KR20210132003A/ko not_active Ceased
- 2019-12-20 MX MX2021007438A patent/MX2021007438A/es unknown
- 2019-12-20 CN CN201980092788.4A patent/CN113661246A/zh active Pending
- 2019-12-20 CN CN201980091966.1A patent/CN113454231A/zh active Pending
- 2019-12-20 WO PCT/CA2019/051898 patent/WO2020124273A1/en not_active Ceased
- 2019-12-20 EP EP19899693.6A patent/EP3898998A4/en not_active Withdrawn
- 2019-12-20 BR BR112021012078-5A patent/BR112021012078A2/pt not_active Application Discontinuation
- 2019-12-20 JP JP2021535804A patent/JP2022514420A/ja active Pending
- 2019-12-20 CA CA3124301A patent/CA3124301A1/en active Pending
- 2019-12-20 JP JP2021535833A patent/JP2022516006A/ja active Pending
- 2019-12-20 PE PE2021000922A patent/PE20212307A1/es unknown
- 2019-12-20 AU AU2019410148A patent/AU2019410148A1/en not_active Abandoned
- 2019-12-20 BR BR112021011730-0A patent/BR112021011730A2/pt not_active Application Discontinuation
- 2019-12-20 WO PCT/CA2019/051899 patent/WO2020124274A1/en not_active Ceased
- 2019-12-20 US US17/415,575 patent/US20220056480A1/en not_active Abandoned
- 2019-12-20 US US17/415,606 patent/US20220380799A1/en not_active Abandoned
- 2019-12-20 SG SG11202106460XA patent/SG11202106460XA/en unknown
- 2019-12-20 KR KR1020217022871A patent/KR20210132002A/ko not_active Ceased
- 2019-12-20 MX MX2021007439A patent/MX2021007439A/es unknown
- 2019-12-20 CA CA3124287A patent/CA3124287A1/en active Pending
-
2021
- 2021-06-17 PH PH12021551436A patent/PH12021551436A1/en unknown
- 2021-06-18 CL CL2021001646A patent/CL2021001646A1/es unknown
- 2021-06-19 IL IL284180A patent/IL284180A/en unknown
- 2021-06-20 IL IL284188A patent/IL284188A/en unknown
- 2021-07-16 CO CONC2021/0009354A patent/CO2021009354A2/es unknown
- 2021-07-20 EC ECSENADI202153474A patent/ECSP21053474A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3898997A1 (en) | 2021-10-27 |
| WO2020124273A1 (en) | 2020-06-25 |
| WO2020124274A1 (en) | 2020-06-25 |
| IL284180A (en) | 2021-08-31 |
| CO2021009354A2 (es) | 2021-11-19 |
| KR20210132003A (ko) | 2021-11-03 |
| AU2019410148A1 (en) | 2021-08-12 |
| US20220056480A1 (en) | 2022-02-24 |
| BR112021011730A2 (pt) | 2021-08-31 |
| TW202039851A (zh) | 2020-11-01 |
| CL2021001646A1 (es) | 2022-02-18 |
| EP3898998A4 (en) | 2022-10-05 |
| US20220380799A1 (en) | 2022-12-01 |
| IL284188A (en) | 2021-08-31 |
| MX2021007439A (es) | 2021-08-05 |
| EP3898997A4 (en) | 2022-11-16 |
| BR112021012078A2 (pt) | 2021-08-31 |
| ECSP21053474A (es) | 2021-11-18 |
| AU2019404639A1 (en) | 2021-08-12 |
| EP3898998A1 (en) | 2021-10-27 |
| KR20210132002A (ko) | 2021-11-03 |
| PE20212307A1 (es) | 2021-12-10 |
| CN113661246A (zh) | 2021-11-16 |
| CA3124287A1 (en) | 2020-06-25 |
| JP2022514420A (ja) | 2022-02-10 |
| JP2022516006A (ja) | 2022-02-24 |
| CA3124301A1 (en) | 2020-06-25 |
| PH12021551436A1 (en) | 2021-12-06 |
| SG11202106460XA (en) | 2021-07-29 |
| CN113454231A (zh) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551436A1 (en) | Modified orthopoxvirus vectors | |
| MX2020007011A (es) | Vectores de vaccinia modificados. | |
| MX2024002073A (es) | Vectores modificados de orthopoxvirus. | |
| MX2021000165A (es) | Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas. | |
| PH12019502518A1 (en) | Alphavirus neoantigen vectors | |
| MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| CO2017009104A2 (es) | Derivados dinucleotidos de purina bis-2’-fluoro-bis-3’-5’-cíclico | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| PH12017501031A1 (en) | Methods and compositions for treating cancer | |
| MY201637A (en) | Natural killer cells and ilc3 cells and uses thereof | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| EP4310500A3 (en) | Methods and compositons for the activation of gamma-delta t-cells | |
| MX2018005286A (es) | Constructo genetico. | |
| NZ739133A (en) | Cellular targeted active ingredient delivery system | |
| MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
| PH12017501993A1 (en) | Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy | |
| MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
| WO2015170158A8 (en) | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation | |
| MX2022004086A (es) | Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos. | |
| WO2014081346A3 (en) | Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus | |
| WO2017049327A3 (en) | In vivo priming of natural killer cells | |
| AR117470A1 (es) | Vectores de orthopoxvirus modificados | |
| EA202091645A1 (ru) | Модифицированные ортопоксвирусные векторы | |
| ZA202210918B (en) | Novel il10 agonists and methods of use thereof |